Drug Search Results

Sumanirole

Alternative Names: sumanirole
Latest Update: 2024-01-16
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sumanirole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease

Trial	Phase	Trial Status	Disease	Primary Completion Date
DA2APD-0075-031	P3	Completed	Parkinson's Disease	None
666E-CNS-0075-021	P3	Completed	Parkinson's Disease	None
M27600011	P3	Terminated	Parkinson's Disease	None

Recent News Events

Date	Type	Title
01/16/2024	PubMed	Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease.
12/19/2023	PubMed	The human neuropsychiatric risk gene Drd2 is necessary for social functioning across evolutionary distant species.
05/26/2023	PubMed	Dopamine D2 receptor on CD4+ T cells is protective against inflammatory responses and signs in a mouse model of rheumatoid arthritis.
06/08/2021	News Article	Motor neurons derived from patients point to new possible drug target for ALS

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions